(Q38150903)

29 August 2017

title

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? (English)

1 reference

29 August 2017

Giulio Gualdi

8

0 references

Andrea Conti

Andrea Conti

6

0 references

Paolo Amerio

Paolo Amerio

2

0 references

Clara De Simone

Clara De Simone

1

0 references

Paolo Gisondi

Paolo Gisondi

7

0 references

author name string

Giuseppe Amoruso

3

1 reference

29 August 2017

Federico Bardazzi

4

1 reference

29 August 2017

Anna Campanati

5

1 reference

29 August 2017

Claudio Guarneri

9

1 reference

29 August 2017

Luca Leoni

10

1 reference

29 August 2017

Francesco Loconsole

11

1 reference

29 August 2017

Annamaria Mazzotta

12

1 reference

29 August 2017

Maria Letizia Musumeci

13

1 reference

29 August 2017

Stefano Piaserico

14

1 reference

29 August 2017

Concetta Potenza

15

1 reference

29 August 2017

Francesca Prestinari

16

1 reference

29 August 2017

language of work or name

English

0 references

publication date

10 October 2013

1 reference

Expert Opinion on Biological Therapy

29 August 2017

published in

1 reference

29 August 2017

volume

13

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1673-1682

1 reference

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Adalimumab for the treatment of psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Safety and efficacy of the tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Dermatological complications and safety of anti-TNF treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.848194

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

21 January 2018

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Differential effect of drug interference in immunogenicity assays

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Etanercept as monotherapy in patients with psoriasis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1517/14712598.2013.848194

Identifiers

DOI

10.1517/14712598.2013.848194

1 reference

29 August 2017

1 reference